Precigen (PGEN)

• Market cap: $1.46B
• 1 day: 2.49%
• 5 days: 3.78%
• 1 month: 26.77%
• 3 months: -9.05%
• 6 months: 2.74%
• Year to date: -3.74%
• 1 year: 167.53%
• 5 years: -49.88%
• 10 years: -84.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Employees: 47